27th Feb 2025 16:18
Oncimmune Holdings Plc
("Oncimmune" or the "Company")
Result of Annual General Meeting
The Annual General Meeting of Oncimmune Holdings Plc was held at 201 Temple Chambers, 3-7 Temple Avenue, London, EC4Y 0DT on 27 February 2025 at 10:30 a.m.
Both resolutions put to members were passed on a poll. Resolution 1 was passed as an ordinary resolution and resolution 2 was passed as a special resolution.
The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:
Resolution | Votes for | % | Votes against | % | Votes withheld |
Resolution 1 (Ordinary) Authority to Allot | 28,185,261 | 99.50% | 140,796 | 0.50% | 49,883 |
Resolution 2 (Special) Disapplication of Statutory Pre-Emption Rights | 28,182,361 | 99.49% | 143,696 | 0.51% | 49,883 |
The full text of each resolution is available in the Notice of Annual General Meeting, published on the Company's website.
For further information:
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)
Nigel Birks (Life Science Specialist Sales)
Ondraya Swanson (Corporate Broking)
+44 (0) 20 7220 0500
Zeus (Joint Broker)
Dominic King
+44 (0)20 3829 5000
About Oncimmune
Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.
Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.
For more information, visit www.oncimmune.com